Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Pelabresib comprises 5 peer-reviewed publications across 5 journals, 1 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Primary Myelofibrosis. Most recent publication: Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial., Nat Med, 2025.
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.
| Trial | Indication | Primary endpoint | Arm | Value |
|---|---|---|---|---|
| NCT04603495 MANIFEST-2 | Primary Myelofibrosis | Number of Participants With Splenic Response by Central Radiology Reads at Week 24 Week 24 | Pelabresib + Ruxolitinib (Experimental Arm) | 141 Participants |
| Placebo + Ruxolitinib (Control Arm) | 76 Participants |
2022–2025: 5 publications.
Pelabresib has been studied in clinical trials for primary myelofibrosis. One pivotal study, NCT04603495 (MANIFEST-2), investigated Pelabresib in combination with ruxolitinib for this condition. The trial assessed the number of participants who achieved a splenic response, as determined by central radiology reads, at Week 24.
In the NCT04603495 trial, the experimental arm, which received Pelabresib + Ruxolitinib, included 141 participants who achieved a splenic response by central radiology reads at Week 24. In the control arm of the same study, which received Placebo + Ruxolitinib, 76 participants achieved a splenic response by central radiology reads at Week 24.
All values presented here are sourced from primary registry reporting; individual scientific papers should be consulted for clinical decisions.
ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.efetch.fcgi